Horizon Discovery Group plc is a biotechnology company specializing in providing gene editing and gene modulation solutions to life science researchers and biopharmaceutical developers. With a focus on precision gene engineering, the company offers a range of technologies based on CRISPR-Cas9, RNA interference and other genome editing platforms to generate genetically defined cell models that support target validation, drug screening and biomarker discovery.
The company’s core offerings include custom and off-the-shelf cell lines engineered to carry disease-relevant mutations, gene editing reagents such as synthetic guide RNAs, and services for knock-out, knock-in and pooled screening applications. Horizon Discovery complements these products with assay development and bioinformatics support, enabling customers to accelerate the identification of novel therapeutic targets and optimize lead compounds in oncology, immunology and rare disease research.
Founded in 2005 and headquartered in Cambridge, United Kingdom, Horizon Discovery operates research and development facilities in both the UK and the United States. The company has established collaborations with academic institutions, pharmaceutical companies and biotechnology firms across Europe, North America and Asia, and has been recognized for pioneering standardized, genetically defined model systems that improve the reproducibility of preclinical research.
In 2020, Horizon Discovery was acquired by PerkinElmer, integrating its gene editing and cell engineering capabilities into a broader portfolio of analytical and diagnostic solutions. This acquisition has expanded the global reach of Horizon Discovery’s technologies, leveraging PerkinElmer’s infrastructure to support a wider range of life science and diagnostic applications.
AI Generated. May Contain Errors.
